278 results on '"Chase, Dana M."'
Search Results
2. The impact of varying levels of residual disease following cytoreductive surgery on survival outcomes in patients with ovarian cancer: a meta-analysis
3. A systematic review of stage IVA cervical cancer treatment: Challenges in the management of an understudied group
4. Prescribers and patients drive maintenance therapy patterns in a community oncology practice: National guidelines versus the real-world experience
5. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
6. Latest advances in immuno-oncology for endometrial cancer: single-agent and combination regimens
7. Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting
8. Preoperative quality of life at time of gynecologic surgery: considerations for postoperative management
9. Factors Associated with Inpatient Narcotic Medication Usage after Robotic-assisted Laparoscopy
10. Robotic-assisted gynecologic surgery in an older population: A comparison study
11. Palliative care and quality of life
12. Contributors
13. Impact of disease progression on health-related quality of life of advanced ovarian cancer patients – Pooled analysis from the PRIMA trial
14. Implicit biases in healthcare: implications and future directions for gynecologic oncology
15. Protein biomarkers in cervicovaginal lavages for detection of endometrial cancer
16. Cervicovaginal metabolome and tumor characteristics for endometrial cancer detection and risk stratification
17. Abstract PR005: Patients with endometrial cancer and benign gynecologic conditions exhibit unique vaginal and rectal microbiomes
18. Gastrointestinal symptoms and diagnosis preceding ovarian cancer diagnosis: Effects on treatment allocation and potential diagnostic delay
19. Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer
20. Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice
21. 1424 Treatment patterns and outcomes by mismatch repair/microsatellite instability (MMR/MSI) status among patients with primary advanced or recurrent endometrial cancer (pA/rEC) in the United States
22. Factors Associated With Grade 3 or 4 Treatment-Related Toxicity in Women With Advanced or Recurrent Cervical Cancer
23. Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: Characteristics associated with toxicity and the effect of substitution with docetaxel: An NRG Oncology/Gynecologic Oncology Group study
24. Updates on drug discovery in ovarian cancer
25. Deciphering the complex interplay between microbiota, HPV, inflammation and cancer through cervicovaginal metabolic profiling
26. Methylation of human papillomavirus 16, 18, 31, and 45 L2 and L1 genes and the cellular DAPK gene: Considerations for use as biomarkers of the progression of cervical neoplasia
27. Preoperative quality of life (QOL) at time of gynecologic surgery: considerations for postoperative management
28. Latest advances in immuno-oncology for endometrial cancer: single-agent and combination regimens
29. Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review
30. The Challenge of Follow-Up in a Low-Income Colposcopy Clinic
31. Vaginal microbiota, genital inflammation, and neoplasia impact immune checkpoint protein profiles in the cervicovaginal microenvironment
32. Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting
33. Socioeconomic factors may contribute to neoadjuvant chemotherapy use in metastatic epithelial ovarian carcinoma
34. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
35. Supportive care for women with gynecologic cancers
36. The development and use of vascular targeted therapy in ovarian cancer
37. The power of hope: Views of Ovarian Cancer patients on how maintenance therapy Affects their Lives (VOCAL).
38. Uterine Inflammatory Myofibroblastic Tumor Showing an Atypical ALK Signal Pattern by FISH and DES-ALK Fusion by RNA Sequencing: A Case Report
39. Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer
40. Palliative Care and Quality of Life
41. Contributors
42. Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis
43. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2
44. 2022-RA-949-ESGO VOCAL (views of ovarian cancer patients-how maintenance therapy affects their lives) study: patient preference for treatment formulation and administration
45. 19 - Palliative care and quality of life
46. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer
47. Changes in Tumor Blood Flow as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) May Predict Activity of Single Agent Bevacizumab in Recurrent Epithelial Ovarian (EOC) and Primary Peritoneal Cancer (PPC) Patients: An exploratory analysis of a Gynecologic Oncology Group Phase II study
48. Quality of life and survival in advanced cervical cancer: A Gynecologic Oncology Group study
49. Cervicovaginal DNA Virome Alterations Are Associated with Genital Inflammation and Microbiota Composition
50. Multi-omics data integration reveals metabolome as the top predictor of the cervicovaginal microenvironment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.